61186372HNC3001 (OrigAMI-5): A Phase 3 Randomized Open-Label Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab Compared to Standard of Care Platinum and Pembrolizumab and 5-FU in Participants with Treatment-Na�ve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
